Cantargia Q2’22: Low Downside Risk at Present Valuation - Redeye
The two main events during and after the second quarter were the positive results from ASCO 2022 and the rights issue. We also discuss Canakinumab's failure in lung cancer and the share's record low market valuation.
ANNONS
The two main events during and after the second quarter were the positive results from ASCO 2022 and the rights issue. We also discuss Canakinumab's failure in lung cancer and the share's record low market valuation.